Rodríguez TM

Language: English
References: 17
Page: 60-62
PDF size: 33.30 Kb.

Text Extraction

Injected drug users constitute the biggest category of hepatitis C virus (HCV) cases in the United States. This group also has the greatest number of new infections per year. It is estimated that about 80%–95% of all users of needles are infected with HCV. Eighty percent of intravenous drug users are infected with HCV during their first year of using needles. The prevalence of hepatitis C is 100% among those that have used intravenous drugs for more than 8 years. This means that 1.5–2 million of the 15 million users of illegal drugs in the United States are infected with HCV.

REFERENCES

1. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19(3): 1-46.

2. Robaeys G, Buntinx F. Treatment of hepatitis C viral infections in substance abusers. Acta Gastroenterol Belg 2005; 68(1): 55-67.

3. Schaefer M, Heinz A, Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? Addiction 2004; 99(9): 1167-75.

4. De Bie J, Robaeys G, Buntinx F. Hepatitis C, interferon alpha and psychiatric co-morbidity in intravenous drug users (IVDU): guidelines for clinical practice. Acta Gastroenterol Belg 2005; 68(1): 68-80.

5. Verrando R, Robaeys G, Mathei C, Buntinx F. Methadone and buprenorphine maintenance therapies for patients with hepatitis C virus infected after intravenous drug use. Acta Gastroenterol Belg 2005; 68(1): 81-5.

6. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004; 40(1): 120-4.

7. Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, Heldwein W, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37(2): 443-51.

8. Robaeys G, Buntinx F, Bottieau E, Bourgeois S, Brenard R, Colle I, De Bie J, et al. Guidelines for the management of chronic hepatitis C in patients infected after substance use. Acta Gastroenterol Belg 2005; 68(1): 38-45.

9. Wejstal R, Alaeus A, Fischler B, Reichard O, Uhnoo I, Weiland O. Swedish National Expert Panel for the treatment of chronic hepatitis C. Chronic hepatitis C: updated Swedish consensus. Scand J Infect Dis 2003; 35(8): 445-51.

10. Raison CL, Broadwell SD, Borisov AS, Manatunga AK, Capuron L, Woolwine BJ, Jacobson IM, Nemeroff CB, Miller AH. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun 2005; 19(1): 23-7.

11. Dalgard O. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin Infect Dis 2005; 40(Suppl.5): S336-8.

12. Dalgard O, Bjoro K, Hellum K, Myrvang B, Skaug K, Gutigard B, Bell H; Construct Group. Treatment of chronic hepatitis C in injecting drug users: 5 years’ follow-up. Eur Addict Res 2002; 8(1): 45-9.

13. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34(1): 188-93.

14. Backmund M, Reimer J, Meyer K, Gerlach JT, Zachoval R. Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment. Clin Infect Dis 2005; 40(Suppl.5): S330-5.

15. Backmund M, Meyer K, Edlin BR. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 2004; 39(10): 1540-3. Epub 2004 Oct 26.

16. Van Beek I, Buckley R, Stewart M, MacDonald M, Kaldor J. Risk factors for hepatitis C virus infection among injecting drug users in Sydney. Genitourin Med 1994; 70(5): 321-4.

17. Fischer B, Haydon E, Rehm J, Krajden M, Reimer J. Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach-the case study of Canada. J Urban Health 2004; 81(3): 428-47.